ADHD is associated with impulsivity, hyperactivity, and trouble with focus, but kids with ADHD may also struggle with motor ...
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
Impulsivity, hyperactivity, and difficulty concentrating are some of the symptoms associated with attention deficit ...
If ADHD goes undiagnosed, it can harm self-esteem and mental health.
An ongoing shortage of medication for attention deficit hyperactivity disorder is affecting millions—and with no end in sight. The Food and Drug Administration first announced a shortage of Adderall, ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...
With an expiration date still more than a year away, here's what the latest details reveal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results